NeoImmuneTech: 2-year survival rate 100% in high-dose NT-I7 group in US CAR-T combination trial; "full-scale technology transfer underway"
Predicted impact: Low
Clinical trial survival data and technology transfer talk; no contract value or revenue size disclosed.